Nephrology Drug Market Analysis, Size, Share & Growth Forecast 2026–2034

SGLT2 Inhibitor CREDENCE, DAPA-CKD, and EMPA-KIDNEY 30 to 40 Percent Composite Kidney Outcome Reduction Across Diabetic and Non-Diabetic CKD Has Established the SGLT2 Inhibitor as the Universal CKD Protective Agent That KDIGO Recommends Regardless of Diabetes Status.AstraZeneca's dapagliflozin DAPA-CKD demonstrated 39% reduction in the composite of sustained GFR decline, end-stage kidney disease, and renal or cardiovascular death in CKD patients regardless of T2DM status, and empagliflozin EMPA-KIDNEY demonstrated similar 28% composite risk reduction across a broader CKD population including normal GFR with significant albuminuria. The SGLT2 mechanism of intraglomerular pressure reduction through tubuloglomerular feedback, proximal tubular sodium reabsorption inhibition, and metabolic effects creates renal protection independent of glucose lowering that operates through haemodynamic and metabolic pathways distinct from the renin-angiotensin system blockade that had been the ceiling of renoprotective therapy. KDIGO guidelines updated in 2022 and 2024 recommend SGLT2 inhibitors for all CKD patients with eGFR above 20 mL/min and urine albumin-creatinine ratio above 200 mg/g as the standard of care alongside ACEi/ARB therapy.

IgA Nephropathy Targeted Therapy Expansion From Tarpeyo Mucosal Immunosuppression Through Factor B Inhibition to APRIL and BLyS Blockade Is Building the Mechanism-Specific Precision Treatment Spectrum for the Leading Cause of Primary Glomerular Disease.Bayer's finerenone FIDELIO-DKD and FIGARO-DKD demonstrated 18% and 13% reduction in cardiorenal composite outcomes in diabetic kidney disease patients on top of maximally tolerated RAAS blockade, and the FIDELITY pooled analysis confirmed consistent renal and cardiovascular benefit across the full spectrum of diabetic CKD from stage G1 to G5. The non-steroidal MRA selectivity avoids the hyperkalaemia and gynaecomastia dose-limiting effects of steroidal spironolactone and eplerenone, enabling full therapeutic dosing in diabetic CKD patients where aldosterone-mediated renal inflammation and fibrosis are key drivers of progression that RAAS blockade alone cannot adequately suppress. The CONFIDENCE trial testing finerenone plus empagliflozin combination is generating data that will determine whether additive cardiorenal protection from dual MRA and SGLT2 mechanism is achievable beyond the sequential addition of each agent to background ACEi.

Patiromer and SZC Potassium Binders Enabling Continued RAAS Inhibitor Use in CKD With Hyperkalaemia Are Preserving the Renoprotective and Cardioprotective RAAS Benefit for the High-Risk Patients Whose Hyperkalaemia Previously Required RAAS Dose Reduction or Discontinuation.Novartis's iptacopan factor B inhibitor demonstrated 35% proteinuria reduction in IgA nephropathy in APPLAUSE-IgAN, and Apellis Pharmaceuticals's pegcetacoplan C3 inhibitor demonstrated 64% proteinuria reduction in C3 glomerulopathy in VALIANT, establishing complement inhibition at multiple pathway levels as clinically active in immune-complex glomerular diseases previously managed only with supportive care and non-specific immunosuppression. The IgA nephropathy landscape has transformed from a disease without approved therapy to one with multiple approved and advancing agents in under 5 years, with Travere Therapeutics's Filspari, Calliditas Therapeutics's Tarpeyo, Vera Therapeutics's atacicept, and complement inhibitors representing four distinct mechanisms advancing simultaneously. The ATLAS trial mapping IgA nephropathy galactose-deficient IgA1 levels as a predictive biomarker for treatment response is establishing precision approaches that may guide selection among the multiple available mechanisms based on immunological disease subtype.

For related market intelligence, see the Pharmaceutical Market.